Octapharma Biopharmaceuticals GmbH – we know the score

Expertise, experience and commitment are the basis for excellent work and perfect results. Since the founding of Octapharma Biopharmaceuticals GmbH in 1997, our experience in the area of research and development in the field of human cell lines has evolved extensively, resulting in the maturation of an effective, product-oriented biotechnology firm.
Our core competence is the development of recombinant pharmaceuticals as a modern alternative to plasma products.

The demand for recombinant therapies is steadily increasing. The proof from market statistics is quite impressive: from 2002 to 2005, the market share for recombinant proteins in 25 research companies rose by approximately 8% overall. The example of the Factor VIII product, which is derived from plasma, demonstrates this exceptionally clear-the shift of plasma-derived Factor VIII to recombinant Factor VII was reflected in a  turnover share increase and rapid growth of 96%.
Our work confirms these trend-setting and innovative discoveries, which undoubtly makes clear that Octapharma Biopharmaceuticals GmbH is on the right path.

Human Cells for Better Compatibility

For the production of proteins with characteristics identical to those of humans, we use human cells, thus ensuring far better compatibility with the products for patients than the frequently-used hamster lines. Herein, all theoretical research work is very close to our heart: we do not only want to be pioneers in progressive science, but also hope that what we increase the quality of life in the best possible way for the people that it affects, such as those afflicted with hemophilia.